-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code ...

ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on Febru ...

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the fourth quarter of 2025, the Small Company Fund (Investor shares) fell 1.50%, behind the Russell 2000® Growth index's 1.22% gain. Real estate and telecommunications businesses led the benchmark's performance for the quarter. The Fund was down 11.46% in 2025, significantly lagging the Index’s 13.0 ...

Core Insights - The article highlights the increasing federal focus on deep brain neurostimulation as a promising therapy for conditions such as TBI, PTSD, stroke recovery, and Alzheimer's disease, with Nexalin Technology, Inc. playing a significant role in this emerging field [1][4][10] Legislative Developments - Recent bipartisan Congressional initiatives have expanded federal support for deep brain neurostimulation research, particularly through the U.S. Department of Veterans Affairs (VA) and the National Institutes of Health (NIH) [1][4] - H.R. 7091, introduced on January 15, 2026, aims to expand clinical trials for deep brain neurostimulation and establish a compassionate use pathway within the VA system [7] - The Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, includes provisions for neuromodulation research focused on stroke recovery among veterans, signed into law by President Trump [7] - The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, expands NIH-supported research using deep brain stimulation for Alzheimer's and Parkinson's diseases, also signed into law by President Trump [7] Company Initiatives - Nexalin Technology's DIFS™ technology is recognized as a sophisticated form of non-invasive deep brain neurostimulation and is currently being evaluated in research with UC San Diego and the San Diego VA veterans' community [2][5] - The company is actively engaged in policy advocacy to support the inclusion of deep brain neurostimulation in federal legislation, which has raised awareness of its therapeutic potential among policymakers [8][9] - Nexalin believes that the expanding federal support for neuromodulation research aligns with its strategic focus on developing non-invasive technologies to address significant unmet medical needs [5][9] Market Opportunity - Conditions such as TBI, PTSD, stroke-related neurological impairment, Alzheimer's disease, and Parkinson's disease represent multi-billion-dollar addressable markets with significant unmet medical needs [10] - As federal research initiatives expand, Nexalin is positioned to advance emerging neurostimulation therapies within the VA system and the broader healthcare infrastructure [10][11]

Core Viewpoint - Aethlon Medical, Inc. is set to present at the Emerging Growth Conference on February 25, 2026, highlighting its focus on developing medical products for cancer and life-threatening infectious diseases [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, specializing in the development of the Hemopurifier, which targets pathogenic substances in biological fluids [1] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, addressing unmet needs in oncology and infectious diseases [1] Product Details - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses [1] - The device operates extracorporeally with a blood pump, utilizing plasma separation, size exclusion, and affinity binding to target mannose-rich surfaces on EVs and viruses [1] Conference Information - The Emerging Growth Conference provides a platform for public companies to present their innovations and engage with investors, featuring a live interactive format [1] - Aethlon's CEO and CFO will participate in a fireside chat and answer questions from attendees, with an archived webcast available for those unable to attend live [1]

White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry."We believe the future of the cochlear implant industry is fully implanted devices ...

Invitation-only program at Houston Methodist, one of the top heart transplant centers in the U.S., highlights the growing need for SynCardia Total Artificial Heart technology. Training initiative at Houston Methodist is expected to enable expanded adoption of the SynCardia Total Artificial Heart through further education. TUCSON, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first ...

Core Viewpoint - Anteris Technologies Global Corp. is actively participating in two major healthcare conferences, showcasing its commitment to advancing medical devices for heart function restoration [1][4]. Group 1: Conference Details - Anteris will present at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, featuring a fireside chat with analyst Joshua Jennings [2]. - The Barclays 28th Annual Healthcare Conference will take place on March 10, 2026, with a fireside chat led by analyst Matt Miksic [3]. - Both conferences will include 1x1 meetings and will be accessible via webcasts, which will be archived for up to 90 days [2][3]. Group 2: Company Overview - Anteris Technologies is a global structural heart company focused on designing and commercializing innovative medical devices [4]. - The company is headquartered in Australia and has a significant operational presence in Minneapolis, USA, emphasizing a science-driven approach [4]. - Anteris' lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [5].

Headquartered in Tempe, Align Technology, Inc. (ALGN) designs and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners. With a market cap of nearly $13.6 billion, it operates through its clear aligner and imaging/CAD-CAM segments and delivers orthodontic treatments, digital scanning systems, software platforms, 3D printing solutions, and integrated services. Over the past 52 weeks, ALGN stock has fallen 4.1%, while the S&P 500 Index ($SPX) surged roughly 13%, leaving shares t ...

Company Overview - Johnson & Johnson (J&J) is a leading company in the multitrillion-dollar global healthcare industry, with total healthcare spending in the U.S. surpassing $5.3 trillion in 2024 and growing at mid- to high single-digit rates [3] - The company develops and sells a wide range of pharmaceutical drugs and medical devices, with over 75% of its sales coming from products that hold top-two market share positions in their respective applications [4] Financial Strength - J&J has a strong financial position, allowing it to invest in new product development, acquire emerging competitors, and consistently raise its dividend [5] - The stock currently yields 2.1%, with management having raised the dividend for 63 consecutive years, making it a reliable income source for investors [6] - J&J is one of only two companies with the highest available credit rating (AAA), ensuring access to debt when needed [6] Market Position and Growth Potential - With a market capitalization approaching $590 billion, J&J is one of the world's largest companies, indicating stability rather than rapid wealth generation [7] - Management believes that the business could accelerate to double-digit growth by the end of this decade, suggesting potential upside for investors [7]